Quick Answer
Nuvation Bio Inc. reported Diluted EPS of $0.60 per share (loss) for fiscal year 2025.
Nuvation Bio Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.60 | +71.6% |
| 2024 | -$2.11 | -502.9% |
| 2023 | -$0.35 | +27.1% |
| 2022 | -$0.48 | -9.1% |
| 2021 | -$0.44 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | -6.7% | +5.9% |
| June 30, 2025 | -$0.17 | +91.0% | -6.3% |
| March 31, 2025 | -$0.16 | -128.6% | -6.7% |
| September 30, 2024 | -$0.15 | -66.7% | +92.1% |
| June 30, 2024 | -$1.89 | -2000.0% | -2600.0% |
| March 31, 2024 | -$0.07 | +30.0% | +22.2% |
| September 30, 2023 | -$0.09 | +25.0% | +0.0% |
| June 30, 2023 | -$0.09 | +43.8% | +10.0% |
- Nuvation Bio Inc. showed an increase of +71.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvation Bio Inc.’s diluted eps has declined by 36.4% (from $0.44 per share (loss) to $0.60 per share (loss)).
- The most recent figure is from Nuvation Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: